Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stauch

Showing results (161-170 of 161) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 161 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Pageof 17

Showing results (161-170 of 161) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 161 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Pageof 17